Mylan Bid Gets Rejected, But Generic-Drugmaker Rises

By | April 4, 2014

Scalper1 News

Generic-drug makers weren’t spared in Friday’s market sell-off, but Mylan (MYL) still managed to buck the overall downtrend as it held on to a small gain. The stock, up as much as 7% in early trading, closed with a 77-cent gain, or 2%, to 50.63 in heavy volume. It is rebounding off a second pullback to the 10-week moving average after clearing a 44.83 flat-base buy point in January. Mylan had been in talks to acquire Swedish generic-drug maker Scalper1 News

Scalper1 News